Drug Trial Radar · NCT00063479
Bisphosphonate Treatment of Osteogenesis Imperfecta
Last checked: Nov 20, 2026Latest source record: Jun 1, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
158
Actual
Start
Jun 2003
Primary completion
May 2007
Study completion May 2007
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jun 30, 2003
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 3 months, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this trial is to evaluate whether the investigational medication is safe, effective and has the ability to increase spine bone density in osteogenesis imperfecta (OI) patients.
Conditions
- Osteogenesis Imperfecta
Interventions
Zoledronic AcidDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in lumbar spine bone mineral density at month 12 relative to baseline
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
UCLA - Division of Pediatric Nephrology
Los Angeles, California
Alfred I. DuPont Hospital for Children
Wilmington, Delaware
Intermountain Orthopedics
Boise, Idaho
St. Jude Children's Research Hospital
Peoria, Illinois
Children's Hospital
Omaha, Nebraska
Children's Hospital Medical Center
Cincinnati, Ohio
Children's Hospital
Columbus, Ohio
Oregon Health Sciences University
Portland, Oregon
Vanderbilt University Medical Center
Nashville, Tennessee
Texas Children's Hosptial
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.